Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025

Core Insights - Monopar Therapeutics Inc. is presenting new data from the Phase 2 ALXN1840-WD-204 copper balance study at the AASLD conference, highlighting the company's focus on innovative treatments for unmet medical needs [1][2] Study Findings - The oral presentation by Professor Aftab Ala indicates that treatment with ALXN1840 (tiomolybdate choline) resulted in a rapid and sustained improvement in daily copper balance in Wilson disease patients, primarily through increased fecal copper excretion [2] - The mean daily copper balance among patients treated with ALXN1840 (n=8) showed significant improvement compared to pre-treatment baseline, with positive results observed during both the initial 15 mg once-daily dosing period (days 1-28) and the entire treatment duration (days 1-39) [3] Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company with a focus on late-stage ALXN1840 for Wilson disease and various radiopharmaceutical programs, including MNPR-101-Zr for imaging advanced cancers and MNPR-101-Lu and MNPR-101-Ac225 for treating advanced cancers [5]